| __timestamp | Amicus Therapeutics, Inc. | BeiGene, Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 6930000 |
| Thursday, January 1, 2015 | 47269000 | 7311000 |
| Friday, January 1, 2016 | 71151000 | 20097000 |
| Sunday, January 1, 2017 | 88671000 | 62602000 |
| Monday, January 1, 2018 | 127200000 | 195385000 |
| Tuesday, January 1, 2019 | 169861000 | 388249000 |
| Wednesday, January 1, 2020 | 156407000 | 600176000 |
| Friday, January 1, 2021 | 192710000 | 990123000 |
| Saturday, January 1, 2022 | 213041000 | 1277852000 |
| Sunday, January 1, 2023 | 275270000 | 1504501000 |
Unleashing the power of data
In the dynamic world of biotechnology, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of BeiGene, Ltd. and Amicus Therapeutics, Inc. from 2014 to 2023. Over this period, BeiGene's SG&A expenses skyrocketed by an astounding 21,600%, reflecting its aggressive expansion and market penetration strategies. In contrast, Amicus Therapeutics saw a more modest increase of approximately 1,230%, indicating steady growth. By 2023, BeiGene's expenses were over five times higher than Amicus's, highlighting its rapid scaling efforts. This divergence underscores the different strategic paths these companies have taken in the competitive biotech landscape. Investors and industry analysts should consider these trends when evaluating the operational efficiency and growth potential of these firms.
Operational Costs Compared: SG&A Analysis of GSK plc and BeiGene, Ltd.
Cost Management Insights: SG&A Expenses for Biogen Inc. and BeiGene, Ltd.
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Insmed Incorporated
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Catalent, Inc.
Comparing SG&A Expenses: BeiGene, Ltd. vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: BeiGene, Ltd. vs MannKind Corporation
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Geron Corporation
Amicus Therapeutics, Inc. or Vericel Corporation: Who Manages SG&A Costs Better?
Amicus Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Travere Therapeutics, Inc.